AR and melanoma: In contrast to previous studies in melanoma and hepatocellular carcinoma reporting reduced ING3 levels in aggressive cancers [54], our analyses of primary prostate tumors showed that high levels of ING3 predict poorer outcome in patients with low AR levels.